Year in Review

Rates of comprehensive biomarker testing and clinical trial participation were significantly lower for black patients with advanced non–small-cell lung cancer (NSCLC) in the United States compared with white patients. Read More ›

Year in Review

Capmatinib in MET Exon 14–Mutated Advanced NSCLC (GEOMETRY Mono-1 Study)

AACR & ASCO 2021 – Midyear Review

Capmatinib offers deep and durable responses with a manageable toxicity for patients with MET exon 14–mutated advanced profile non–small-cell lung cancer (NSCLC) regardless of line of therapy. Read More ›

Videos Year in Review

Combination Therapies and New Molecular Targets—Presentations from AACR 2021

By David Spigel, MD

AACR & ASCO 2021 – Midyear Review

Dr David Spigel reviews potentially practice-changing data on EGFR-TKI combination therapies in NSCLC, new approaches to advanced NSCLC and CNS involvement, and hopeful early data with novel targeted agents. Read More ›

Videos Year in Review

Practice-Changing Data in NSCLC from ASCO 2021

By Mark A. Socinski, MD

AACR & ASCO 2021 – Midyear Review

Dr Mark Socinski provides his insights into important new data on EGFR inhibitors and immunotherapy in the first-line setting for NSCLC. Read More ›

Videos Year in Review

Exciting New Data Presented on NSCLC at AACR 2021

By David Spigel, MD

AACR & ASCO 2021 – Midyear Review

Dr David Spigel discusses key presentations on immunotherapy and targeted therapy in the neoadjuvant and adjuvant settings in NSCLC. Read More ›

Year in Review

Comparison of Aumolertinib and Gefitinib in First-Line Treatment of EGFR-Mutated NSCLC

AACR & ASCO 2021 – Midyear Review

Aumolertinib, a novel EGFR inhibitor, shows prolonged clinical benefit in a randomized comparison with gefitinib as first-line therapy in advanced non–small-cell lung cancer (NSCLC) with EGFR exon 19 del or L858R mutation. Read More ›

Year in Review

Pooled Analyses of Immune-Related Adverse Events and Efficacy from IMpower130, IMpower132, and IMpower150

AACR & ASCO 2021 – Midyear Review

Overall survival is longer for patients with advanced non–small-cell lung cancer who received atezolizumab and had immune-related adverse events versus patients who received atezolizumab and did not have immune-related adverse events. Read More ›

Year in Review

Clinical Outcomes for Plasma-Based Genomic Profiling versus Tissue Testing in Advanced NSCLC (NILE)

AACR & ASCO 2021 – Midyear Review

Therapeutic outcomes based on plasma-based comprehensive genomic profiling are comparable to published tissue-based targeted therapy clinical outcomes in non–small-cell lung cancer (NSCLC). Read More ›

Year in Review

Anti–PD-L1 Therapy in Combination with Chemotherapy versus Immunotherapy Alone in First-Line NSCLC with PD-L1 Score 1% to 49%

AACR & ASCO 2021 – Midyear Review

Chemotherapy plus immunotherapy (IO) may improve efficacy outcomes over IO alone in most patients with advanced non–small-cell lung cancer (NSCLC) and programmed death ligand 1 (PD-L1) scores between 1% and 49%. Read More ›

Year in Review

Page 9 of 9